American Journal of Preventive Medicine
Volume 16, Issue 2 , Pages 134-140, February 1999

Screening for hemochromatosis:

A public health perspective

  • Mary E. Cogswell, DrPH

      Affiliations

    • Maternal and Child Nutrition Branch, and Office of the Director, Atlanta, Georgia, USA
    • Corresponding Author InformationAddress correspondence and reprints requests to: Mary E. Cogswell, DrPH, CDC, Mail Stop K-25, 4770 Buford Highway, NE, Atlanta, GA 30341
    • ,
  • Wylie Burke, MD, PhD

      Affiliations

    • Division of Nutrition and Physical Activity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, University of Washington, Seattle, Washington, USA
    • ,
  • Sharon M. McDonnell, MD, MPH

      Affiliations

    • Maternal and Child Nutrition Branch, and Office of the Director, Atlanta, Georgia, USA
    • ,
  • Adele L. Franks, MD

      Affiliations

    • Maternal and Child Nutrition Branch, and Office of the Director, Atlanta, Georgia, USA

Abstract 

Context: The discovery of the HFE gene in 1996 has introduced DNA testing as a possible tool for screening and diagnosis of hemochromatosis and increased interest in the disorder. Population screening using transferrin saturation has been advocated by experts to permit early detection and treatment with phlebotomy before the onset of clinical disease.

Methods: Based on a literature review, we consider the relative risks and merits of two screening tests as part of a broader look at the evidence required for the recommendation of universal screening for hemochromatosis.

Results: Several questions must be answered before universal screening can be recommended. Uncertainties remain about the penetrance and preventable disease burden, laboratory standardization, and optimal strategies to minimize potential risks of screening for hemochromatosis.

Conclusions: As a common genetic disorder with simple, effective therapy, hemochromatosis offers a model for other genetically influenced chronic diseases that some day may have interventions to improve prognosis. Resolution of questions related to prevention of chronic diseases from hemochromatosis, therefore, will have broad usefulness in the future.

Keywords:  hemochromatosis, genetic screening, diagnosis, iron, preventive medicine, chronic disease

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0749-3797(98)00141-X

American Journal of Preventive Medicine
Volume 16, Issue 2 , Pages 134-140, February 1999

Article Tools

* Image Usage & Resolution